GlassScriptPhysician profile
Edward Lemuel Esteb
NPI 1245339795
$1,294.49
in general payments reported to CMS, 2019-2025
11 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $634 · 2020: $588 · 2021: $73.30.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sunovion Pharmaceuticals INC. | $242.10 | 2019 | |
| Janssen Pharmaceuticals, INC | $211.70 | 2020 | |
| Pfizer INC. | $175.73 | 2020-2021 | |
| Novo Nordisk INC | $154.31 | 2019-2020 | |
| Sanofi-Aventis U.S. LLC | $132.84 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $117.98 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $104.80 | 2019 | |
| Merck Sharp & Dohme LLC | $89.08 | 2019-2020 | |
| Amarin Pharma, INC. | $28.51 | 2020 | |
| Glaxosmithkline, LLC. | $22.04 | 2021 | |
| Novartis Pharmaceuticals Corporation | $15.40 | 2020 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Edward Esteb listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.